First United Bank Trust lessened its stake in Becton Dickinson and Co (NYSE:BDX) by 7.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 6,483 shares of the medical instruments supplier’s stock after selling 512 shares during the quarter. First United Bank Trust’s holdings in Becton Dickinson and were worth $1,640,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. TRUE Private Wealth Advisors acquired a new stake in shares of Becton Dickinson and during the 2nd quarter worth approximately $25,000. Allworth Financial LP grew its position in shares of Becton Dickinson and by 386.4% during the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 85 shares during the period. Hexavest Inc. acquired a new stake in shares of Becton Dickinson and during the 2nd quarter worth approximately $28,000. Lipe & Dalton acquired a new stake in shares of Becton Dickinson and during the 2nd quarter worth approximately $28,000. Finally, CX Institutional acquired a new stake in shares of Becton Dickinson and during the 3rd quarter worth approximately $31,000. Hedge funds and other institutional investors own 84.21% of the company’s stock.
In related news, CEO Vincent A. Forlenza sold 11,532 shares of Becton Dickinson and stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the transaction, the chief executive officer now owns 218,671 shares of the company’s stock, valued at approximately $56,937,554.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Charles R. Bodner sold 1,514 shares of Becton Dickinson and stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $260.08, for a total transaction of $393,761.12. Following the transaction, the senior vice president now directly owns 5,180 shares in the company, valued at approximately $1,347,214.40. The disclosure for this sale can be found here. Insiders have sold a total of 37,249 shares of company stock worth $9,616,803 in the last three months. 0.12% of the stock is owned by insiders.
Becton Dickinson and stock opened at $252.86 on Friday. The company’s 50 day simple moving average is $253.69 and its 200 day simple moving average is $245.85. Becton Dickinson and Co has a fifty-two week low of $208.62 and a fifty-two week high of $264.74. The firm has a market capitalization of $66.90 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 1.58 and a beta of 1.12. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping the consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The business had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same quarter last year, the firm earned $2.91 EPS. Becton Dickinson and’s quarterly revenue was up 1.7% compared to the same quarter last year. As a group, analysts predict that Becton Dickinson and Co will post 11.68 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend was Friday, September 6th. Becton Dickinson and’s payout ratio is 27.97%.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: What is Forex?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.